Impact of Stem Cell Source on Secondary Steroid for Chronic GVHD After Allogeneic Hematopoietic Cell Transplantation

Overview

Journal Int J Hematol

Specialty Hematology

Date 2024 Nov 25

PMID 39585531

Authors

Kazuhiro Sanda

Shigeo Fuji

Yuma Tada

Yasuhiro Shingai

Hidenori Kasahara

Sayako Yuda

Takafumi Yokota

Jun Ishikawa

Affiliations

Soon will be listed here.

Abstract

Inappropriate discontinuation of immunosuppressive drugs (ISD) following allogeneic hematopoietic cell transplantation (HCT) can lead to the development of chronic graft-versus-host disease (cGVHD) and necessitate the reintroduction of ISD. However, only a few studies have compared the discontinuation rates of secondary steroid for cGVHD between different stem cell sources. We retrospectively evaluated 191 patients who underwent HCT at our institution to determine the discontinuation rates of secondary steroids for cGVHD. 50 patients (26.7%) received secondary steroid for cGVHD. After additional steroid for cGVHD, the 2-year cumulative steroid discontinuation rates were 50.0%, 0%, 8.3%, 44.0%, and 40.0% for MSD, uPBSC, uBM, UCB, PTCy-haplo, respectively (P = 0.0313). Patients transplanted with uBM or uPBSC had significantly lower cumulative discontinuation rates of additional steroids for cGVHD compared to those transplanted with other stem cell sources (P < 0.001). Multivariate analysis indicated that the cumulative steroid discontinuation rate was significantly lower in uPBSC or uBM group compared to in MSD group (uPBSC, HR, 0.10; P = 0.024, uBM, HR, 0.13; P = 0.007). Therefore, careful steroid reduction or additional treatment for cGVHD is necessary in patients transplanted with uBM and uPBSC.

References

Atsuta Y, Hirakawa A, Nakasone H, Kurosawa S, Oshima K, Sakai R . Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016; 22(9):1702-1709. DOI: 10.1016/j.bbmt.2016.05.019. View

Matsumura-Kimoto Y, Inamoto Y, Tajima K, Kawajiri A, Tanaka T, Hirakawa T . Association of Cumulative Steroid Dose with Risk of Infection after Treatment for Severe Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2016; 22(6):1102-1107. DOI: 10.1016/j.bbmt.2016.02.020. View

Cheon J, Lee Y, Jo J, Kweon K, Koh S, Min Y . Late complications and quality of life assessment for survivors receiving allogeneic hematopoietic stem cell transplantation. Support Care Cancer. 2020; 29(2):975-986. DOI: 10.1007/s00520-020-05572-0. View

Flowers M . Progress in the management of chronic GVHD insights into novel therapies to treat and manage GVHD lasting longer than 12 Months. Best Pract Res Clin Haematol. 2021; 34(1):101253. DOI: 10.1016/j.beha.2021.101253. View

Fatobene G, Storer B, Salit R, Lee S, Martin P, Cheng G . Disability related to chronic graft --host disease after alternative donor hematopoietic cell transplantation. Haematologica. 2018; 104(4):835-843. PMC: 6442956. DOI: 10.3324/haematol.2018.202754. View

Nakamae H . Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide. Int J Hematol. 2022; 116(4):465-481. DOI: 10.1007/s12185-022-03428-3. View

Sorror M, Maris M, Storb R, Baron F, Sandmaier B, Maloney D . Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106(8):2912-9. PMC: 1895304. DOI: 10.1182/blood-2005-05-2004. View

Armand P, Kim H, Logan B, Wang Z, Alyea E, Kalaycio M . Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014; 123(23):3664-71. PMC: 4047501. DOI: 10.1182/blood-2014-01-552984. View

Inamoto Y, White J, Ito R, Martin P, Fatobene G, Ito A . Comparison of characteristics and outcomes of late acute and NIH chronic GVHD between Japanese and white patients. Blood Adv. 2019; 3(18):2764-2777. PMC: 6759734. DOI: 10.1182/bloodadvances.2019000386. View

10.

Holtan S, DeFor T, Lazaryan A, Bejanyan N, Arora M, Brunstein C . Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015; 125(8):1333-8. PMC: 4335084. DOI: 10.1182/blood-2014-10-609032. View

11.

Schoemans H, Lee S, Ferrara J, Wolff D, Levine J, Schultz K . EBMT-NIH-CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant. 2018; 53(11):1401-1415. PMC: 6786777. DOI: 10.1038/s41409-018-0204-7. View

12.

Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M . Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009; 15(3):367-9. PMC: 3110087. DOI: 10.1016/j.bbmt.2008.12.497. View

13.

Kanda Y . Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2012; 48(3):452-8. PMC: 3590441. DOI: 10.1038/bmt.2012.244. View

14.

Othman J, Greenwood M, Moore J, Larsen S, Watson A, Arthur C . Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG. Biol Blood Marrow Transplant. 2020; 26(10):1868-1875. DOI: 10.1016/j.bbmt.2020.06.030. View

15.

Finke J, Schmoor C, Bethge W, Ottinger H, Stelljes M, Volin L . Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial. Lancet Haematol. 2017; 4(6):e293-e301. DOI: 10.1016/S2352-3026(17)30081-9. View

16.

Shiratori S, Sugita J, Fuji S, Aoki J, Sawa M, Ozawa Y . Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors. Bone Marrow Transplant. 2021; 56(9):2231-2240. DOI: 10.1038/s41409-021-01314-w. View

17.

Kuriyama K, Fuji S, Inamoto Y, Tajima K, Tanaka T, Inoue Y . Impact of low-dose rabbit anti-thymocyte globulin in unrelated hematopoietic stem cell transplantation. Int J Hematol. 2016; 103(4):453-60. DOI: 10.1007/s12185-016-1947-9. View

18.

Fuji S, Ueno N, Hiramoto N, Asakura Y, Yakushijin K, Kamiyama Y . Reduced-intensity conditioning regimen with low-dose ATG-F for unrelated bone marrow transplant is associated with lower non-relapse mortality than a regimen with low-dose TBI: a single-center retrospective analysis of 103 cases. Int J Hematol. 2013; 98(5):608-14. DOI: 10.1007/s12185-013-1449-y. View

19.

Lee S, Nguyen T, Onstad L, Bar M, Krakow E, Salit R . Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017; 24(3):555-562. PMC: 5826880. DOI: 10.1016/j.bbmt.2017.10.042. View

20.

Chen G, Onstad L, Martin P, Carpenter P, Pidala J, Arai S . Durable discontinuation of systemic therapy in patients affected by chronic graft--host disease. Haematologica. 2022; 108(2):483-489. PMC: 9890023. DOI: 10.3324/haematol.2021.279814. View